Drug-Drug Interactions (DDI) Archives

Case Study

PBPK Model Informs Antibody-Drug Conjugate Label for DDIs Without Clinical Trials

Genentech was developing polatuzumab vedotin (Polivy), an anti-CD79b-vc-monomethyl auristatin E (MMAE) antibody-drug conjugate (ADC) to…

Jim Gallagher2022年4月11日

Case Study

Simcyp Simulator を使用した小児における Guanfacine の DDI 責任の判定

Guanfacine (Intuniv® XR) extended release (GXR) is an orally administered, selective alpha2A-adrenergic receptor agonist, non-stimulant…

Jim Gallagher2021年8月26日

Case Study

Eliglustat for Gaucher Disease: Quantifying the Impact of Pharmacogenetic Status on DDIs

In 2014, Eliglustat (Cerdelga®) was approved by the FDA as the first long-term treatment for…

Jim Gallagher2021年8月26日

Case Study

Aripiprazole lauroxil: PBPK for Dosing Regimen and DDI Identification

Aripiprazole lauroxil (Aristada®) was approved by the FDA for treating schizophrenia in adults in October…

Jim Gallagher2021年8月12日

Case Study

PBPK Assists with DDI Prediction Without a Rifampin Study for Cobimetinib

Cobimetinib (Cotellic®), approved by the US FDA in 2015, is a kinase inhibitor for treating…

Jim Gallagher2021年8月12日

Case Study

Simcyp Simulatorを使用するDDIレギュレトリーの広告塔：Ibrutinib (Imbruvica®)

Pharmacylics and J&J sought to bring ibrutinib, its new tyrosine kinase inhibitor therapy targeting rare…

Jim Gallagher2021年7月29日

Case Study

鎌状赤血球症治療用のVoxelotor：用量予測モデルを活用して臨床試験を実施することなくDDIを予測

In November 2019, the US FDA granted accelerated approval for Oxbryta™ (voxelotor) tablets for the…

Jim Gallagher2021年7月14日

On-Demand Webinar

Predicting the Effect of the Dulaglutide-Mediated Gastric Emptying Delay on Drug Exposure

The European Medicines Agency (EMA) recently approved dulaglutide (Trulicity®) at higher doses (3 mg and…

Jim Gallagher2021年4月1日

Case Study

ガルデルマ社、AKLIEF®（トリファロテン）のFDA承認を取得

In October 2019, Galderma announced that the U.S. FDA approved AKLIEF® (trifarotene) Cream, 0.005% for the…

Certara2020年11月9日

Publication

Metformin and Cimetidine: Physiologically-based Pharmacokinetic Modeling to Investigate Transporter Mediated Drug–drug Interactions

Danielle Pillsbury2016年6月1日

Powered by Translations.com GlobalLink Web Software

薬物間相互作用（Drug-Drug Interactions：DDI）

PBPK Model Informs Antibody-Drug Conjugate Label for DDIs Without Clinical Trials

Simcyp Simulator を使用した小児における Guanfacine の DDI 責任の判定

Eliglustat for Gaucher Disease: Quantifying the Impact of Pharmacogenetic Status on DDIs

Aripiprazole lauroxil: PBPK for Dosing Regimen and DDI Identification

PBPK Assists with DDI Prediction Without a Rifampin Study for Cobimetinib

Simcyp Simulatorを使用するDDIレギュレトリーの広告塔：Ibrutinib (Imbruvica®)

鎌状赤血球症治療用のVoxelotor：用量予測モデルを活用して臨床試験を実施することなくDDIを予測

Predicting the Effect of the Dulaglutide-Mediated Gastric Emptying Delay on Drug Exposure

ガルデルマ社、AKLIEF®（トリファロテン）のFDA承認を取得

Metformin and Cimetidine: Physiologically-based Pharmacokinetic Modeling to Investigate Transporter Mediated Drug–drug Interactions

メルマガ登録

クイックアクセス

ソリューション

お問合せ